Thaҫi D, Pinter A, Sebastian M, et al. - Researchers conducted this multicentre, randomized, open-label, assessor-blinded, active-comparator-controlled phase IIIb study to compare the safety and effectiveness of guselkumab, a fully human interleukin-23 antibody, with those of fumaric acid esters (FAE) in individuals with moderate-to-severe plaque psoriasis who are naive to systemic treatment. Patients who were eligible randomized to receive guselkumab 100 mg by subcutaneous injection or oral FAE according to local label guidelines. Fifty-six of 60 individuals completed guselkumab treatment and 36 of 59 completed FAE treatment through week 24. Data reported that adverse events incidence was lower with guselkumab than with FAE. In systemic-treatment-naive patients with moderate-to-severe plaque psoriasis, guselkumab showed superiority over FAE through 24 weeks.